Skip to content
Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
The latest updates in hemonc research
The 23rd Congress of the European Hematology Association (EHA) 2018, took place on the 14–17 June in Stockholm, Sweden. EHA 2018 brought together leading experts in hematological oncology from around the world, who presented the latest updates in key areas.
Highlights in hematological oncology from this year’s conference include promising results from many clinical trials, including DESTINY and CAPTIVATE, advances in the use of biomarkers to detect disease and inform treatment strategy, and the latest applications of immunotherapy.
Immuno-Oncology
Immunotherapy is playing an ever-increasing role in hemonc.
Agents including antibodies, immune checkpoint inhibitors and CAR T-cells are already revolutionizing the treatment landscape of multiple hematological malignancies.
View more
Measurable Residual Disease
MRD is an arguably invaluable tool.
MRD holds great potential as prognostic indicator, which could be used to tailor treatment plans and indicate treatment response. MRD was discussed in the context of both research and clinical practice at EHA 2018.
View more
Precision Medicine
Personalizing treatment plans using biomarker analysis is a new frontier in hemonc.
This promises to improve treatment efficacy and reduce unnecessary therapies and toxicities.
View more
Press Briefs
Watch the breaking press briefs featuring the latest results in hemonc research.
Highlights include updates on new CAR T-cell products, clinical trials such as AHL2011, and data collaboration initiatives.
View more